BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25876881)

  • 1. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.
    Knight DR; Giglio S; Huntington PG; Korman TM; Kotsanas D; Moore CV; Paterson DL; Prendergast L; Huber CA; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV
    J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients.
    Reigadas E; Muñoz-Pacheco P; Vázquez-Cuesta S; Alcalá L; Marín M; Martin A; Bouza E
    Anaerobe; 2017 Dec; 48():269-272. PubMed ID: 28988773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012.
    Lachowicz D; Pituch H; Obuch-Woszczatyński P
    Anaerobe; 2015 Feb; 31():37-41. PubMed ID: 25242196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of MCB3681 against Clostridium difficile strains.
    Rashid MU; Dalhoff A; Weintraub A; Nord CE
    Anaerobe; 2014 Aug; 28():216-9. PubMed ID: 25016084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
    Tkhawkho L; Nitzan O; Pastukh N; Brodsky D; Jackson K; Peretz A
    J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J; Vernon J; Pilling S; Morris K; Nicholson S; Shearman S; Longshaw C; Wilcox MH;
    Clin Microbiol Infect; 2018 Jul; 24(7):724-731. PubMed ID: 29066403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
    Baines SD; O'Connor R; Freeman J; Fawley WN; Harmanus C; Mastrantonio P; Kuijper EJ; Wilcox MH
    J Antimicrob Chemother; 2008 Nov; 62(5):1046-52. PubMed ID: 18693234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
    Nyc O; Tejkalova R; Kriz Z; Ruzicka F; Kubicek L; Matejkova J; Kuijper E; Krutova M
    Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea.
    Kim J; Kang JO; Pai H; Choi TY
    Int J Antimicrob Agents; 2012 Jul; 40(1):24-9. PubMed ID: 22578765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study.
    Freeman J; Vernon J; Pilling S; Morris K; Nicolson S; Shearman S; Clark E; Palacios-Fabrega JA; Wilcox M;
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):169-177. PubMed ID: 31811507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea.
    Byun JH; Kim H; Kim JL; Kim D; Jeong SH; Shin JH; Kim YA; Shin JH; Shin KS; Uh Y
    Anaerobe; 2019 Dec; 60():102106. PubMed ID: 31655214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
    O'Connor R; Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection.
    Richardson C; Kim P; Lee C; Bersenas A; Weese JS
    Anaerobe; 2015 Jun; 33():105-8. PubMed ID: 25769665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
    Adams HM; Li X; Mascio C; Chesnel L; Palmer KL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4139-47. PubMed ID: 25941217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole.
    Adler A; Miller-Roll T; Bradenstein R; Block C; Mendelson B; Parizade M; Paitan Y; Schwartz D; Peled N; Carmeli Y; Schwaber MJ
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):21-4. PubMed ID: 26116225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden.
    Rashid MU; Lozano HM; Weintraub A; Nord CE
    Anaerobe; 2013 Apr; 20():32-5. PubMed ID: 23454525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.